Literature DB >> 8209852

Overexpression of p53 protein in adenocarcinoma of the pancreas.

J A DiGiuseppe1, R H Hruban, S N Goodman, M Polak, F M van den Berg, D C Allison, J L Cameron, G J Offerhaus.   

Abstract

Mutations in the p53 tumor suppressor gene are frequently identified in human neoplasms. These mutations may be associated with stabilization and, therefore, with overexpression of the p53 protein product as determined by immunohistochemical staining. Using a new antigen retrieval method and a polyclonal antibody to p53 (CM-1), the authors examined 48 formalin-fixed paraffin-embedded adenocarcinomas of the pancreas for overexpression of the p53 gene product. These 48 carcinomas were obtained from a series of patients with well-documented clinical histories and extensive follow-up. The carcinomas had been analyzed previously for K-ras gene mutations, tumor ploidy, and tumor proliferating index. Specific diffuse nuclear staining for the p53 protein was identified in 19 of the 48 (40%) infiltrating carcinomas examined. Focal or negative staining was seen in the remaining 29 cases (60%). In addition, 17 of the neoplasms contained synchronous in situ carcinomas; two (12%) of these displayed diffuse nuclear staining for the p53 protein. Overexpression of p53 was associated with aneuploidy (P = .05), which had been a poor prognosticator in this series of adenocarcinomas of the pancreas. Although overexpression of p53 appeared to be associated with poor prognosis (hazard ratio, 1.8; P = .07), this was not statistically significant. Overexpression of p53 was not significantly associated with K-ras oncogene mutations or tumor proliferating index. The authors conclude that overexpression of the p53 protein occurs frequently in invasive adenocarcinomas of the pancreas and in some in situ carcinomas, as well.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8209852     DOI: 10.1093/ajcp/101.6.684

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  54 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Loss of heterozygosity or intragenic mutation, which comes first?

Authors:  R E Wilentz; P Argani; R H Hruban
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

3.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

4.  Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.

Authors:  Sally E Dowen; Tatjana Crnogorac-Jurcevic; Rathi Gangeswaran; Mikkel Hansen; Jyrki J Eloranta; Vipul Bhakta; Teresa A Brentnall; Jutta Lüttges; Gunther Klöppel; Nick R Lemoine
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

5.  Down-regulation of Bax-interacting factor 1 in human pancreatic ductal adenocarcinoma.

Authors:  Domenico Coppola; James Helm; Msoumeh Ghayouri; Mokenge P Malafa; Hong-Gang Wang
Journal:  Pancreas       Date:  2011-04       Impact factor: 3.327

6.  Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.

Authors:  H Suwa; G Ohshio; N Okada; Z Wang; M Fukumoto; T Imamura; M Imamura
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

7.  Genetics and pathology of pancreatic cancer.

Authors:  Jordan M Winter; Anirban Maitra; Charles J Yeo
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

8.  Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer.

Authors:  Yi Zhong; Anne Macgregor-Das; Tyler Saunders; Martin C Whittle; Alvin Makohon-Moore; Zachary A Kohutek; Justin Poling; Brian T Herbst; Breanna M Javier; Leslie Cope; Steven D Leach; Sunil R Hingorani; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2016-09-16       Impact factor: 12.531

9.  p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb.

Authors:  Berthold Gerdes; Annette Ramaswamy; Andreas Ziegler; Sven A Lang; Michael Kersting; Renate Baumann; Anja Wild; Roland Moll; Matthias Rothmund; Detlef K Bartsch
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

10.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.